Follow Our Live Coverage of COVID-19 Developments

Narcan Nasal Spray Approved to Counter Narcotic Painkiller Overdose

First-of-its-kind drug sanctioned to reverse effects of heroin or oxycodone use

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

THURSDAY, Nov. 19, 2015 (HealthDay News) -- Narcan (naloxone hydrochloride) nasal spray has been approved by the U.S. Food and Drug Administration to stop or reverse an overdose of opioids, a class of narcotic drugs that includes the prescription medication oxycodone (Oxycontin) and the illicit drug heroin.

Symptoms of overdose with these drugs could include shallow breathing and difficulty waking a person. Drug overdoses have surpassed traffic accidents as the leading cause of injury death in the United States, the FDA said in a news release.

Narcan, if given soon enough, can reverse the effects of an overdose in as little as two minutes, the agency said. The drug was approved previously as an injection. However, many first responders believe a nasal spray is easier to deliver and avoids the possibility of needle contamination, the FDA said. However, the drug is not meant to substitute for immediate medical care.

In clinical testing, the nasal spray given in one nostril had about the same effectiveness as the drug's injected form, the FDA said.

If the drug is given to people who are dependent on narcotic painkillers or heroin, they may develop symptoms of severe opioid withdrawal, including body aches, diarrhea, rapid heartbeat, fever, runny nose and sneezing, the agency said.

Narcan nasal spray is distributed by Adapt Pharma, based in Radnor, Penn.

More information

The FDA has more about this approval.


Last Updated: